AF
TVTX icon

Allworth Financial’s Travere Therapeutics TVTX Stock Holding History

Allworth Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.4K Buy
834
+28
+3% +$1.24K ﹤0.01% 2536
2026
Q1 		$23.9K Sell
806
-1,415
-64% -$42.3K ﹤0.01% 2859
2025
Q4 		$84.9K Buy
2,221
+1,569
+241% +$51K ﹤0.01% 1853
2025
Q3 		$15.6K Buy
652
+252
+63% +$4.74K ﹤0.01% 2855
2025
Q2 		$5.92K Sell
400
-26
-6% -$431 ﹤0.01% 3174
2025
Q1 		$7.51K Sell
426
-46
-10% -$934 ﹤0.01% 2557
2024
Q4 		$9.19K Sell
472
-96
-17% -$1.7K ﹤0.01% 2473
2024
Q3 		$7.95K Hold
568
– – ﹤0.01% 2368
2024
Q2 		$5.57K Buy
+568
New +$3.83K ﹤0.01% 2476
2023
Q4 		– Sell
-48
Closed -$430 – 3625
2023
Q3 		$430 Buy
48
+29
+153% +$409 ﹤0.01% 3075
2023
Q2 		$292 Sell
19
-23
-55% -$418 ﹤0.01% 3025
2023
Q1 		$945 Buy
+42
New +$893 ﹤0.01% 2692
2022
Q4 		– Sell
-50
Closed -$1K – 3201
2022
Q3 		$1K Buy
50
+33
+194% +$853 ﹤0.01% 2523
2022
Q2 		$0 Buy
+17
New +$428 ﹤0.01% 2824

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allworth Financial's TVTX Position: Q2 2026 in Review

Allworth Financial increased its Travere Therapeutics (TVTX) stake by 3.5% in Q2 2026, buying an estimated $1.24K and bringing the position to 834 shares worth $47.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

Allworth Financial first reported a position in TVTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $84.9K in Q4 2025. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Allworth Financial held 834 shares of Travere Therapeutics worth $47.4K as of Q2 2026.
  • Allworth Financial bought 28 Travere Therapeutics shares in Q2 2026, an estimated $1.24K.
  • Travere Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2536 holding.
  • Allworth Financial first reported a position in Travere Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Allworth Financial's Travere Therapeutics position peaked at $84.9K in Q4 2025.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.